Results 261 to 270 of about 710,958 (307)
Some of the next articles are maybe not open access.
Current Problems in Cancer, 1987
Lung cancer stands as the most important malignant neoplasm in the United States because of its high prevalence, increasing incidence, high rate of mortality, and great potential for prevention through the control of cigarette smoking. The World Health Organization (WHO) classification of lung cancer identifies four major types: squamous cell carcinoma,
C M, Haskell, E C, Holmes
openaire +3 more sources
Lung cancer stands as the most important malignant neoplasm in the United States because of its high prevalence, increasing incidence, high rate of mortality, and great potential for prevention through the control of cigarette smoking. The World Health Organization (WHO) classification of lung cancer identifies four major types: squamous cell carcinoma,
C M, Haskell, E C, Holmes
openaire +3 more sources
Mobocertinib in non-small cell lung cancer
Drugs of Today, 2022Tyrosine kinase inhibitors (TKIs) have provided great benefit for patients with EGFR-mutant non-small cell lung cancer (NSCLC). While prior TKIs have demonstrated limited efficacy against exon 20 insertion mutations of EGFR (EGFR Ex20Ins), mobocertinib (TAK-788) is designed to specifically inhibit these Ex20Ins mutations. In a phase I/II clinical trial,
Shengwu, Liu, Kristen E, Lowder
openaire +2 more sources
Savolitinib for non-small cell lung cancer
Drugs of Today, 2023Savolitinib is a highly selective MET tyrosine kinase inhibitor. MET is involved in numerous cellular processes such as proliferation, differentiation and the formation of distant metastases. MET amplification and MET overexpression are quite common in many cancers, but MET exon 14 skipping alteration is most common in non-small cell lung cancer (NSCLC)
Magdalena, Zaborowska-Szmi +3 more
openaire +2 more sources
Nature Reviews Disease Primers
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose CT, the implementation of novel surgical and ...
Lizza E L Hendriks +2 more
exaly +4 more sources
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose CT, the implementation of novel surgical and ...
Lizza E L Hendriks +2 more
exaly +4 more sources
Therapy of non-small cell lung cancer [PDF]
Lung Cancer, 1995 Several regimes can provide clinical answers and longer survival to patients with small cell carcinoma of the lungs who respond to treatment. Moreover there is frequently also suppression of pathological symptoms of the disease in these patients.
openaire +3 more sources
Bevacizumab in Non-Small Cell Lung Cancer
Drugs, 2008Lung cancer continues to be the leading cause of cancer death in Western countries. The median survival time for advanced non-small cell lung cancer (NSCLC) remains poor and chemotherapy is the treatment of choice for most patients with metastatic NSCLC. Platinum-based chemotherapy has long been the standard of care for advanced NSCLC. The formation of
Di Costanzo F. +6 more
openaire +2 more sources
Anthacyclines in non-small cell lung cancer
Lung Cancer, 2001The literature concerning the use of anthracyclines in the treatment of non-small cell lung cancer (NSCLC) is reviewed here. Overall, the activity of doxorubicin (DOXO) is unsatisfactory, whereas, the analogous epidoxorubicin (EPI) yields a 30% response rate (RR) when administered at intermediate-high doses.
P, Pronzato +4 more
openaire +2 more sources
Advanced non-small cell lung cancer
Current Treatment Options in Oncology, 2001The treatment of advanced non-small cell lung cancer requires histologic proof of diagnosis, careful staging, and assessment of each patient's performance status and comorbidities. For patients with stage IIIB (pleural effusion) and stage IV disease who have a Cancer and Leukemia Group B performance status (PS) of 0 to 1, appropriate management ...
M J, Edelman, S L, Khanwani
openaire +2 more sources
Screening for Non-Small Cell Lung Cancer
Seminars in Oncology, 2005Lung cancer is the leading cause of cancer mortality and is usually discovered at an advanced stage, when treatment is generally not effective. Many researchers have investigated the value of screening for lung cancer, which would theoretically allow earlier detection and more effective treatment.
Rendell W, Ashton, James R, Jett
openaire +2 more sources
Necitumumab for non-small cell lung cancer
Expert Opinion on Biological Therapy, 2015Targeting the EGFR pathway is a rational approach to treat patients with advanced NSCLC. Necitumumab, a second-generation recombinant fully human immunoglobulin G1 monoclonal antibody directed against EGFR, has recently been assessed in combination with first-line cisplatin-based chemotherapy.This article reviews literature on necitumumab development ...
Laurent, Greillier +2 more
openaire +2 more sources